



The Michigan Vision-related Anxiety Questionnaire

TECHNOLOGY NUMBER: 2021-206



Technology ID

2021-206

Category

Content

Software & Content

Further information

Drew Bennett

andbenne@umich.edu

Innovation Partnerships Tech

Marketing Team

IPInventions@umich.edu

OVERVIEW

- Validated Patient Reported Outcomes (PRO) measure
- Focused on psychosocial screening and monitoring for patients with inherited retinal degenerations
- Measure can be utilized in therapeutic clinical trials for measuring the benefit of an investigational therapy on a patient's vision related anxiety

LICENSING INQUIRIES: Effective January 1, 2024 The University of Michigan has partnered with [MAPI Research Trust](#) for the licensing, management and distribution of all Michigan developed Clinical Outcome Assessments (COA's). MAPI is the recognized global leader in the COA space and has exceptional resources to assist with scale based distribution, instructional design, documentation as well as deep partnerships with [ICON](#) language services for translation services. All inquiries for this measure, regardless of if it is a research or commercial request should be directed to MAPI.

MAPI Research Trust - [Michigan Vision Related Anxiety Questionnaire \(MVAQ\)](#)

[View online](#)



INNOVATION

An important new feature of the MVAQ is its ability to relate psychosocial reports to a retinal physiologic pathway. Furthermore, the MVAQ disability scores exhibit correlations with VA, phenotype, and self-reported feelings. Other PRO measures ask about a patient's feelings or concerns, but their responses cannot be linked to the pathologic defect underlying their visual impairment. In contrast, the MVAQ allows a clinician to map the concerns of the patient into an actionable area for improvement. As opposed to knowing that a patient experiences "fear" or "worry", with the MVAQ a clinician can identify whether a patient's rod dysfunction is the predominant cause of their anxiety, and recommend accommodations to their living setting and vision-related activities to address these specific anxiety-provoking situations.

The current study demonstrates psychometric validation of items pertaining to vision related anxiety in patients with IRDs and collectively form the MVAQ. The MVAQ measures vision-related anxiety due to dysfunction in either a predominantly cone pathway or a rod pathway. It can be used as a screening tool to direct the attention of a clinician to counseling and psychosocial interventions, as well as to measure baseline and follow-up vision related anxiety for targeted low vision rehabilitation and psychotherapy. Finally, the MVAQ may also be incorporated in therapeutic clinical trials to understand the benefit of a novel therapeutic intervention for reducing a patient's vision-related anxiety.

ADDITIONAL DETAILS

LICENSING INQUIRIES: Effective January 1, 2024 The University of Michigan has partnered with MAPI Research Trust for the licensing, management and distribution of all Michigan developed Clinical Outcome Assessments (COA's). MAPI is the recognized global leader in the COA space and has exceptional resources to assist with scale based distribution, instructional design, documentation as well as deep partnerships with ICON language services for translation services. All inquiries for this measure, regardless of if it is a research or commercial request should be directed to MAPI.

MAPI Research Trust - [Michigan Vision Related Anxiety Questionnaire \(MVAQ\)](#)